SCHEMBL451068

SCHEMBL451068

Cc1ccc(-n2c(CN(C)S(=O)(=O)c3ccc([N+](=O)[O-])cc3)nc3ccccc3c2=O)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
TDO2 P48775 2/20 0.48
IDO2 Q6ZQW0 2/20 0.48
IDO1 P14902 1/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 3/20 0.48
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
C1R P00736 1/20 0.45
HIF1A Q16665 1/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450956 0.92 ALDH1A1 (0.57) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL449848 0.89 ALDH1A1 (0.54) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL448912 0.88 ALDH1A1 (0.53) ALDH1A1TDO2IDO2IDO1POLB
SCHEMBL454849 0.88 ALDH1A1 (0.53) ALDH1A1TDO2IDO2POLBMAPT
SCHEMBL451572 0.87 ALDH1A1 (0.52) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL450854 0.87 ALDH1A1 (0.52) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL452025 0.86 ALDH1A1 (0.55) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL452019 0.86 ALDH1A1 (0.51) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL449990 0.86 ALDH1A1 (0.51) ALDH1A1TDO2IDO2MAPTKDM4E
SCHEMBL448343 0.85 ALDH1A1 (0.52) ALDH1A1TDO2IDO2IDO1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885TDO2 3664/4885IDO2 4127/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885TDO2 3664/4885IDO2 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.